Illumina Inc experienced a significant boost in its stock price, reflecting strong market sentiment and positive company fundamentals.
Illumina Inc (NASDAQ:ILMN) saw its stock surge by 7.25% yesterday, closing at $273.90. This uptick comes amidst a backdrop of impressive year-to-date performance and ongoing developments in the genomics sector.
Advertisement
Illumina Inc
ILMN.US
ILMN.US
Illumina Inc
WealthAwesomeMarket cap
$41.36B
P/E
47.6x
52W high
$277.95
52W low
$88.00
1W change
+11.71%
Beta
1.47
Analyst Price Targets
Based on 20 analysts covering ILMN · as of Sep 17, 2026
Wall Street analysts forecast ILMN stock price to fall 26.0% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
C$202.65
-26.0% Upside
Current Price
C$273.90
Last close
Analyst Breakdown (20 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ILMN's historical volatility
30-Day Vol
54.4%
Annualized
90-Day Vol
46.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$327.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$290.70 | C$240.95 – C$350.72 |
| 60 trading days | C$308.53 | C$236.60 – C$402.32 |
| 90 trading days | C$327.45 | C$236.57 – C$453.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are taking note of Illumina's robust growth trajectory, particularly as the company continues to innovate and expand its market share in genomic sequencing and related technologies.
7.25% Surge in Stock Price
Illumina's stock has appreciated by 21.82% over the last 30 days and an impressive 103.87% year-to-date, indicating strong investor confidence.
Bull case
The recent surge shows strong momentum in Illumina's core business. The company has seen significant gains in sequencing and multiomics, and the outlook for the upcoming fiscal year looks positive.
Bear case
Despite the positive movement, some analysts worry about valuation. They suggest that Illumina's stock may be overvalued by about 37% based on current earnings projections.
Strong Business Momentum
Advertisement
Illumina's recent performance has been boosted by advancements in its sequencing technology and services. The core sequencing business is gaining traction, especially in clinical markets. This has led to a 9.5% year-over-year revenue growth in the second quarter of 2026, highlighting strong demand for genomic solutions.
Valuation Concerns Persist
Even with the positive momentum, analysts remain cautious about Illumina's valuation. With a P/E ratio of 47.63, many believe the stock is overvalued by around 37% compared to its fair value estimate of $199.63. This raises questions about whether the current stock price reflects sustainable growth or speculative froth.
Future Outlook
Looking ahead, Illumina is focused on expanding its market presence and enhancing its product offerings. With a projected revenue growth of 6.3% for 2026, the company aims to capitalize on the growing demand for genomic diagnostics. However, challenges such as regulatory uncertainties in key markets like China could impact its growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
